You are here: Industry Insights > Novartis

News List

Novartis, Cadila Healthcare lead digital marketing space for ankylosing spondylitis in India: GlobalData expresspharma
May 21, 2021
Novartis and Cadila Healthcare are the only companies to offer support to AS patients through digital channels, finds GlobalData.
Novartis announces delivery of one billion courses of anti-malarial treatment expresspharma
May 21, 2021
Along with malaria prevention tools and better diagnostics, ACTs remain a key component of the global drive to reach malaria elimination.
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment worldpharmanews
May 20, 2021
Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was supplied without profit to malaria-endemic countries around the globe.
Cross-industry alliance launches to increase awareness of cell and gene therapies in the UK pharmatimes
May 19, 2021
A new cross-industry alliance between leading pharma and biotech companies has launched in a bid to raise awareness and boost understanding of cell and gene therapies in the UK.
Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche's Actemra/RoActemra® worldpharmanews
May 08, 2021
Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient (API) for Roche's Actemra/RoActemra® (tocilizumab), a treatment for rheumatoid ...
Novartis’ MS therapy Kesimpta wins NICE backing pharmatimes
April 22, 2021
Novartis’ Kesimpta has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of relapsing remitting multiple sclerosis (RRMS) in adult patients.
Novartis bags EU, UK licences for MS therapy Kesimpta pharmatimes
April 09, 2021
Novartis has received green lights from both the European Commission and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to market its multiple sclerosis (MS) therapy Kesimpta (ofatumumab).
Artios, Novartis form cancer therapies collaboration pharmatimes
April 08, 2021
Artios Pharma and Novartis have formed a global research collaboration to discover and validate next generation DNA damage response (DDR) targets to enhance the Swiss drugmaker's radioligand therapies (RLT).
Novartis UK announces further HRT patch stock issues pharmatimes
April 08, 2021
Novartis says it is expecting an additional temporary stock shortage of its HRT patch Estradot TTS-75, due to “manufacturing constraints”.
Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP) americanpharmaceuticalreview
April 07, 2021
Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page